Larimar Therapeutics, Inc. - 8-K Filing
Larimar Therapeutics reports Q3 2026 results, announces completed BLA submission for nomlabofusp in Friedreich’s ataxia (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $LRMR